Heart Failure With Reduced Ejection Fraction (HFrEF) Pipeline Summary

DelveInsight’s, “Heart Failure With Reduced Ejection Fraction (HFrEF) - Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Heart Failure With Reduced Ejection Fraction (HFrEF) pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Heart Failure With Reduced Ejection Fraction (HFrEF): Understanding

Heart Failure With Reduced Ejection Fraction (HFrEF): Overview

Heart failure with reduced ejection fraction (HFrEF) is a clinical syndrome characterized by the inability of the heart to pump sufficient blood to meet the body's metabolic demands due to impaired left ventricular systolic function, typically defined as a left ventricular ejection fraction (LVEF) of ?40%. It commonly results from ischemic heart disease, myocardial infarction, hypertension, dilated cardiomyopathy, valvular heart disease, or genetic and inflammatory disorders. Progressive ventricular remodeling, neurohormonal activation, and myocardial injury lead to declining cardiac output and worsening heart failure.

Patients typically present with exertional dyspnea, fatigue, reduced exercise tolerance, orthopnea, paroxysmal nocturnal dyspnea, peripheral edema, and weight gain due to fluid retention. HFrEF is associated with frequent hospitalizations, reduced quality of life, and substantial morbidity and mortality despite advances in therapy.

The pathophysiology of HFrEF involves loss of myocardial contractility accompanied by chronic activation of the sympathetic nervous system and the renin–angiotensin–aldosterone system (RAAS), which initially compensates for reduced cardiac output but ultimately promotes adverse ventricular remodeling, fibrosis, inflammation, and progressive systolic dysfunction. Increased ventricular wall stress, elevated filling pressures, endothelial dysfunction, and impaired renal perfusion contribute to fluid retention and worsening congestion.

Diagnosis is based on compatible clinical symptoms and signs together with objective evidence of reduced LVEF on transthoracic echocardiography, the cornerstone imaging modality. Additional evaluation includes measurement of B-type natriuretic peptide (BNP) or NT-proBNP, electrocardiography, chest radiography, laboratory investigations, cardiac magnetic resonance imaging when indicated, coronary assessment, and functional testing to identify the underlying cause and disease severity.

Treatment of HFrEF focuses on improving symptoms, slowing disease progression, reducing hospitalization, and lowering cardiovascular mortality through guideline-directed medical therapy (GDMT). The four foundational drug classes include an angiotensin receptor-neprilysin inhibitor (ARNI) or an ACE inhibitor/ARB when ARNI is not feasible, an evidence-based ?-blocker, a mineralocorticoid receptor antagonist (MRA), and a sodium-glucose cotransporter-2 (SGLT2) inhibitor. Loop diuretics are used to relieve congestion, while additional therapies such as ivabradine, vericiguat, hydralazine–isosorbide dinitrate, intravenous iron, and cardiac myosin activators may be appropriate for selected patients. Device therapies including implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT) are recommended for eligible patients, whereas left ventricular assist devices (LVADs) or heart transplantation are reserved for advanced refractory heart failure.

"Heart Failure With Reduced Ejection Fraction (HFrEF)- Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Heart Failure With Reduced Ejection Fraction (HFrEF) pipeline landscape is provided which includes the disease overview and Heart Failure With Reduced Ejection Fraction (HFrEF) treatment guidelines. The assessment part of the report embraces, in depth Heart Failure With Reduced Ejection Fraction (HFrEF) commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Heart Failure With Reduced Ejection Fraction (HFrEF) collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Heart Failure With Reduced Ejection Fraction (HFrEF) R&D. The therapies under development are focused on novel approaches to treat/improve Heart Failure With Reduced Ejection Fraction (HFrEF).

Heart Failure With Reduced Ejection Fraction (HFrEF) Emerging Drugs Chapters

This segment of the Heart Failure With Reduced Ejection Fraction (HFrEF) report encloses its detailed analysis of various drugs in different stages of clinical development, including Phase III, II, I, Preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Heart Failure With Reduced Ejection Fraction (HFrEF) Emerging Drugs

AC01: AnaCardio AB

AC01 is an investigational oral ghrelin receptor agonist with calcium-sensitizing inotropic properties being developed by AnaCardio for the treatment of chronic heart failure with reduced ejection fraction (HFrEF). The therapy is designed to enhance myocardial contractility without substantially increasing heart rate or myocardial oxygen demand, with the goal of improving cardiac function while maintaining a favorable safety profile. Early clinical studies have shown that AC01 is generally well tolerated and supports further evaluation in HFrEF patients. It is currently being investigated in the Phase II GOAL-HF2 trial to evaluate its safety and efficacy over 12 weeks in patients with chronic advanced HFrEF.

HJB647: Novartis

HJB647 is an investigational oral small-molecule therapy being developed by Novartis for the treatment of chronic heart failure with reduced ejection fraction (HFrEF) and mildly reduced ejection fraction (HFmrEF). Although its precise mechanism of action has not yet been publicly disclosed, the candidate is intended to improve cardiac function while maintaining an acceptable safety and tolerability profile. HJB647 is currently being evaluated in a randomized, double-blind, placebo-controlled Phase I crossover study assessing its safety, tolerability, and pharmacokinetics at two dose levels in patients with stable HFrEF/HFmrEF. The study will also characterize its pharmacokinetic profile to support further clinical development in heart failure.

Further product details are provided in the report……..

Heart Failure With Reduced Ejection Fraction (HFrEF): Therapeutic Assessment

This segment of the report provides insights about the different Heart Failure With Reduced Ejection Fraction (HFrEF) drugs segregated based on following parameters that define the scope of the report, such as:

• Major Players in Heart Failure With Reduced Ejection Fraction (HFrEF)
• There are approx. 10+ key companies which are developing the therapies for Heart Failure With Reduced Ejection Fraction (HFrEF). The companies which have their Heart Failure With Reduced Ejection Fraction (HFrEF) drug candidates in the most advanced stage, i.e. Phase III include, Amgen.

• Phases

DelveInsight’s report covers around 12+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration

Heart Failure With Reduced Ejection Fraction (HFrEF) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

• Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Heart Failure With Reduced Ejection Fraction (HFrEF): Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, II, I, preclinical and discovery stage. It also analyses Heart Failure With Reduced Ejection Fraction (HFrEF) therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Heart Failure With Reduced Ejection Fraction (HFrEF) drugs.

Heart Failure With Reduced Ejection Fraction (HFrEF) Report Insights

• Heart Failure With Reduced Ejection Fraction (HFrEF) Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Heart Failure With Reduced Ejection Fraction (HFrEF) Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Heart Failure With Reduced Ejection Fraction (HFrEF) drugs?
• How many Heart Failure With Reduced Ejection Fraction (HFrEF) drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Heart Failure With Reduced Ejection Fraction (HFrEF)?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Heart Failure With Reduced Ejection Fraction (HFrEF) therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Heart Failure With Reduced Ejection Fraction (HFrEF) and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Amgen
• AnaCardio AB
• Novartis
• Medley Therapeutics
• Qanatpharma
• Medera Group
• Novo Nordisk
• Salubris Biotherapeutics Inc

Key Products

• Maridebart cafraglutide
• AC01
• HJB647
• YAP101
• Lumacaftor
• SRD 001
• CDR132L
• JK07